Metabolism: Warburg’s vision
Genetic tools help to dissect the relationship between aerobic glycolysis and anabolic metabolism in the retinas of mice.
- University of Washington, United States
Rod-shaped cells at the back of our eyes allow us to see in dim light. Each day, around dawn, these rod cells shed their tips (LaVail, 1976), and the lost material is replaced with newly built proteins and other macromolecules made further down in the same cell (Anderson et al., 1980; Young, 1967).
Cancer cells growing in a tumor also have a high demand for newly built macromolecules. In the early 1920s, the German physiologist Otto Warburg reported on a specialized type of metabolism that converts most of the glucose taken up by a cell into lactate, rather than carbon dioxide and water as usually happens, even when oxygen is abundant (Warburg et al., 1924). Two of the tissues in which Warburg discovered this type of metabolism, which is often referred to as "aerobic glycolysis", were the very same tissues introduced above, retinas and tumors.
The building of complex macromolecules from simpler building blocks is referred to as anabolism. Recently studies into the metabolism of cancer cells have begun to reveal biochemical details that may link aerobic glycolysis and anabolic activity (Vander Heiden and DeBerardinis, 2017). One of the remarkable features of cancer cells discovered in these studies is that they often produce specific versions (or isoforms) of the enzymes that carry out glycolysis, namely pyruvate kinase (PKM2) and lactate dehydrogenase (LDHA). Not surprisingly, these same isoforms are present in rod cells (Casson et al., 2016; Lindsay et al., 2014; Rajala et al., 2016; Rueda et al., 2016). Now, in eLife, Constance Cepko and colleagues at Harvard Medical School – including Yashodhan Chinchore as first author – report how these two glycolytic enzymes contribute to anabolic metabolism in rod cells from mice (Chinchore et al., 2017).
First, Chinchore et al. inactivated LDHA and PKM2 in mouse rod cells, either with inhibitors or by reducing expression of the genes that encode the enzymes. The resulting rod cells were shorter than normal, as if they did not have enough anabolic activity to counteract the shedding of their tips (Figure 1). In support of this idea, when the mice were kept in constant darkness (which suppresses shedding and renewal of the outer segments), inactivating LDHA or PKM2 had less of an effect. Chinchore et al. then engineered mice in which some cells in the retina made less LDHA or PKM2 while the others were normal. In these 'mosaic' retinas, the only rods that were shorter were the ones with less LDHA or PKM2. This suggests that the enzymes promote anabolism only in the cell in which they are made.
Figure 1
Manipulation of glycolytic enzymes sheds light on the link between aerobic glycolysis and anabolic metabolism.
(A) The tip of the outer segment of a rod cell in the retina regularly sheds and needs to be replaced. Anabolic activity (green) in the same cell builds the macromolecules needed to replace the lost material. Two glycolytic enzymes, called PKM2 and LDHA (light blue circles), are thought to drive the anabolic metabolism of rod cells. (B) Reducing the expression of either of the genes for these enzymes results in rod cells with shorter outer segments, most likely because there is not enough anabolic activity to counteract the shedding. (C) Keeping mice in constant darkness suppresses the shedding and means that rod cells that lack LDHA or PKM2 still have outer segments of a normal length.
Chinchore et al. were concerned that the complete loss of PKM2 or LDHA might have effects that were so devastating that even the essential 'housekeeping' roles of glycolysis in the cell could be compromised. To address that concern, they also used a more 'surgical' approach that specifically slowed glycolysis without eliminating the entire pathway. Fructose-2,6-bisphosphate is an activator of glycolysis. To decrease this chemical in rod cells, Chinchore et al. overexpressed a protein specifically in rods that removes an essential phosphate group from this activator. Slowing glycolysis by this strategy made the rod cells shorter than normal, indicating that flux through the glycolysis pathway is key.
So, what makes PKM2 and LDHA different from other isoforms so that cells requiring rapid growth use them and not the other isoforms? Previous studies showed that these enzymes can be regulated by tyrosine phosphorylation to promote aerobic glycolysis (Hitosugi et al., 2009; Jin et al., 2017). Moreover, exposure to light – which increases the need for anabolic activity – enhances phosphorylation of PKM2 in the retinas of mice (Rajala et al., 2016). Chinchore et al. confirmed this result and then looked for signaling pathways that, when blocked, reduced how much PKM2 was phosphorylated in rod cells. They found that the pathway that responds to fibroblast growth factor (FGF) can control the phosphorylation of PKM2 and LDHA in mouse retinas. The tissue that normally is immediately adjacent to the rod cells, the retinal pigment epithelium, can influence the amount of FGF that a retina is exposed to in an eye. Chinchore et al. found that culturing mouse retinas with this tissue, or with some FGF, boosts how much lactate is produced.
By manipulating the expression of genes involved in aerobic glycolysis in mouse retinas, Chinchore et al. have further revealed how aerobic glycolysis relates to anabolic metabolism. They also show that disrupting any of three different steps in glycolysis can diminish anabolic capacity and cause the rod cells to become shorter. Each of the disruptions tested would have a different biochemical effect on the glycolytic pathway, but what they have in common is that they all cause less lactate to be produced. It is not yet clear why this would compromise anabolic activity, but the genetic tools developed by Chinchore et al. to manipulate glycolysis in rod cells provide new opportunities to answer this question.
References
-
Metabolism of phosphatidylcholine in the frog retinaBiochimica Et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 620:212–226.https://doi.org/10.1016/0005-2760(80)90203-9
-
M-type pyruvate kinase isoforms and lactate dehydrogenase A in the mammalian retina: metabolic implicationsInvestigative Opthalmology & Visual Science 57:66–80.https://doi.org/10.1167/iovs.15-17962
-
The cellular and compartmental profile of mouse retinal glycolysis, tricarboxylic acid cycle, oxidative phosphorylation, and ~P transferring kinasesMolecular Vision 22:847–885.
-
The renewal of photoreceptor cell outer segmentsJournal of Cell Biology 33:61–72.https://doi.org/10.1083/jcb.33.1.61
Article and author information
Author details
Publication history
Copyright
© 2017, Hurley
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,249
- views
-
- 293
- downloads
-
- 6
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Metabolism: Warburg’s vision
eLife 6:e29217.
https://doi.org/10.7554/eLife.29217
Further reading
-
- Biochemistry and Chemical Biology
The hepatitis B virus (HBV) infection is a major global health problem, with chronic infection leading to liver complications and high death toll. Current treatments, such as nucleos(t)ide analogs and interferon-α, effectively suppress viral replication but rarely cure the infection. To address this, new antivirals targeting different components of the HBV molecular machinery are being developed. Here we investigated the hepatitis B core protein (HBc) that forms the viral capsids and plays a vital role in the HBV life cycle. We explored two distinct binding pockets on the HBV capsid: the central hydrophobic pocket of HBc-dimers and the pocket at the tips of capsid spikes. We synthesized a geranyl dimer that binds to the central pocket with micromolar affinity, and dimeric peptides that bind the spike-tip pocket with sub-micromolar affinity. Cryo-electron microscopy further confirmed the binding of peptide dimers to the capsid spike tips and their capsid-aggregating properties. Finally, we show that the peptide dimers induce HBc aggregation in vitro and in living cells. Our findings highlight two tractable sites within the HBV capsid and provide an alternative strategy to affect HBV capsids.
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Pancreatic KATP channel trafficking defects underlie congenital hyperinsulinism (CHI) cases unresponsive to the KATP channel opener diazoxide, the mainstay medical therapy for CHI. Current clinically used KATP channel inhibitors have been shown to act as pharmacochaperones and restore surface expression of trafficking mutants; however, their therapeutic utility for KATP trafficking-impaired CHI is hindered by high affinity binding, which limits functional recovery of rescued channels. Recent structural studies of KATP channels employing cryo-electron microscopy (cryoEM) have revealed a promiscuous pocket where several known KATP pharmacochaperones bind. The structural knowledge provides a framework for discovering KATP channel pharmacochaperones with desired reversible inhibitory effects to permit functional recovery of rescued channels. Using an AI-based virtual screening technology AtomNet followed by functional validation, we identified a novel compound, termed Aekatperone, which exhibits chaperoning effects on KATP channel trafficking mutations. Aekatperone reversibly inhibits KATP channel activity with a half-maximal inhibitory concentration (IC50) ~9 μM. Mutant channels rescued to the cell surface by Aekatperone showed functional recovery upon washout of the compound. CryoEM structure of KATP bound to Aekatperone revealed distinct binding features compared to known high affinity inhibitor pharmacochaperones. Our findings unveil a KATP pharmacochaperone enabling functional recovery of rescued channels as a promising therapeutic for CHI caused by KATP trafficking defects.
